Juvenile dermatomyositis (JDM) is a rare disease in children that causes fatigue, muscle weakness, and skin rashes. Medicines like steroids and immune-suppressing drugs help, but some kids still have symptoms that last a long time. The goal of treatment is to reach remission—meaning no active signs of the disease.

This study uses information already collected in the CARRA Registry from children newly diagnosed with JDM. We’ll look at their symptoms, muscle strength, and lab results when they first joined and again 12 months later. We want to see which kids reached remission or had mild disease after a year, and if we can predict that from their first visit.

Finding these early signs that can predict remission at 1 year can help doctors decide who may need stronger treatment early on and who might do well with standard care.